Lifecore dispute panel update
This article was originally published in Clinica
Information is emerging about the reason for the indefinite postponement of the FDA's first dispute resolution advisory panel, which happened just a few days before the meeting which was scheduled for June 4 (see Clinica No 957, p 1). Lifecore Biomedical had requested the meeting to challenge the FDA's decision not to approve its Intergel adhesion prevention barrier solution.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.